AHL
RYTM icon

Abel Hall LLC’s Rhythm Pharmaceuticals RYTM Stock Holding History

Abel Hall LLC’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Buy
4,258
+243
+6% +$22K 0.08% 259
2026
Q1 		$349K Buy
4,015
+1,875
+88% +$182K 0.07% 335
2025
Q4 		$229K Buy
+2,140
New +$227K 0.05% 472

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Abel Hall LLC's RYTM Position: Q2 2026 in Review

Abel Hall LLC increased its Rhythm Pharmaceuticals (RYTM) stake by 6.1% in Q2 2026, buying an estimated $22K and bringing the position to 4,258 shares worth $473K. The position accounts for 0.08% of the portfolio, ranked #259.

Abel Hall LLC first reported a position in RYTM in Q4 2025 and has held it in 3 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Abel Hall LLC held 4,258 shares of Rhythm Pharmaceuticals worth $473K as of Q2 2026.
  • Abel Hall LLC bought 243 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $22K.
  • Rhythm Pharmaceuticals made up 0.08% of Abel Hall LLC's portfolio in Q2 2026, its #259 holding.
  • Abel Hall LLC first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.